CRL4CRBN E3 Ligase Complex as a Therapeutic Target in Multiple Myeloma

Multiple myeloma (MM) is the second most common hematological malignancy with a recurrent clinical course. The introduction of immunomodulatory drugs (IMiDs) was one of the milestones in MM therapy leading to a significant improvement in patients' prognosis. Currently, IMiDs are the backbone of MM therapy in newly diagnosed and relapsed/refractory settings. It is now known that IMiDs exert their anti-myeloma activity mainly by binding cereblon (CRBN), the substrate receptor protein of the CRL4 E3 ubiquitin ligase (CRL4(CRBN)) complex. By binding CRBN, IMiDs alter its substrate specificity, leading to ubiquitination and proteasomal degradation of proteins essential for MM cell survival. Following the success of IMiDs, it is not surprising that the possibility of using the CRL4(CRBN) complex's activity to treat MM is being further explored. In this review, we summarize the current state of knowledge about novel players in the MM therapeutic landscape, namely the CRBN E3 ligase modulators (CELMoDs), the next generation of IMiDs with broader biological activity. In addition, we discuss a new strategy of tailored proteolysis called proteolysis targeting chimeras (PROTACs) using the CRL4(CRBN) to degrade typically undruggable proteins, which may have relevance for the treatment of MM and other malignancies in the future.

Automated summary

Multiple myeloma is a common hematological malignancy that can have a recurrent clinical course. Immunomodulatory drugs have significantly improved the prognosis of patients with multiple myeloma. The use of the CRL4(CRBN) complex's activity for treating multiple myeloma is being explored further.